Learn more

LIPOSCIENCE INC

Overview
  • Total Patents
    100
  • GoodIP Patent Rank
    40,724
  • Filing trend
    ⇧ 400.0%
About

LIPOSCIENCE INC has a total of 100 patent applications. It increased the IP activity by 400.0%. Its first patent ever was published in 2000. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets measurement, computer technology and medical technology are HALL EFFECT TECHNOLOGIES LTD, GUANGDONG MEDICAL DEVICES QUALITY SURVEILLANCE AND TEST INST and FOUR PI SYSTEMS CORP.

Patent filings per year

Chart showing LIPOSCIENCE INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Otvos James D 84
#2 Shalaurova Irina Y 48
#3 Bennett Dennis W 30
#4 Wolak-Dinsmore Justyna E 27
#5 Jeyarajah Elias J 26
#6 O'Connell Thomas M 23
#7 Morgan David R 15
#8 Matyus Steven P 13
#9 Mercier Kelly 9
#10 Markham Stephen 8

Latest patents

Publication Filing date Title
WO2020097349A1 Methods to predict liver disease mortality using lipoprotein lp-z
US2019145990A1 Methods and Systems to Detect and Quantify the Amount of LP-X and Other Abnormal Lipoproteins in a Biosample Using NMR Spectroscopy
WO2019051226A1 Multi-parameter metabolic vulnerability index evaluations
US2018112274A1 Methods and Systems for Predicting Colorectal Cancer Incidence and Mortality
EP3177939A1 Cardiovascular risk evaluations using a risk parameter that includes an hdl and inflammatory biomarker interaction parameter
US2015127267A1 Multiple-marker risk parameters predictive of conversion to diabetes
CN106461639A Multiple-marker risk parameters predictive of conversion to diabetes
WO2014059025A1 Nmr quantification of branched chain amino acids
US2013289885A1 CHD risk stratification evaluations for subjects with high levels of large HDL-P
US2013332082A1 Multi-parameter diabetes risk evaluations
US2013328561A1 NMR measurements of NMR biomarker GlycA
US2013325353A1 NMR quantification of TMAO
WO2013003454A2 Quantitative nmr clinical analyzers with automatic nmr temperature sensitivity compensation that accommodate large ambient operational temperature ranges
EP2344890A2 Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
WO2007133593A2 Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements
EP2189802A1 NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation biosamples
CA2542107A1 Methods, systems and computer programs for assessing chd risk using mathematical models that consider in vivo concentration gradients of ldl particle subclasses of discrete size
AU2003285926A8 Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
US6653140B2 Methods for providing personalized lipoprotein-based risk assessments
WO03012416A1 Method of determining presence and concentration of lipoprotein x in blood plasma and serum